medigraphic.com

2016, Number 1

<< Back Next >>

Med Sur 2016; 23 (1)

Crohn’s disease. Review and current concepts

Kúsulas-Delint D, González-Regueiro JA, Rodríguez-Aldama JC, García-Miranda FS, García-Santos RA, Lizardo AE, Gutiérrez-Grobe Y

Language: English
References: 55
Page: 10-20
PDF size: 184.89 Kb.


ABSTRACT

The incidence and prevalence of Crohn’s disease (CD) is increasing worldwide. The economic burden and impact on patients’ quality of life, make an early diagnosis of Crohn’s disease, a priority to induce and maintain remission and prevent long-term complications. It has been described a North to South gradient of prevalence, however, there are only a few reports about the epidemiology of this disease in Latin-American countries, therefore the real prevalence and behavior of the disease in our population is unknown. During the last years, experts have made important advances in the diagnosis and treatment of the disease. However, despite this advances, currently, there is no curative treatment for CD. Recent knowledge of immunomodulatory and biologic therapies in the treatment of inflammatory bowel diseases (IBD) has established new goals in the induction and maintenance of remission of these diseases. This article reviews current knowledge of epidemiological and clinical aspects, an approach in the evaluation of the patient and a brief review on treatment of Crohn’s disease.


REFERENCES

  1. Stange E. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55.

  2. Van Assche G, Dignass A, Panes J. The second European evidence- based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. Journal of Crohn’s and Colitis 2010; 4(1): 7-27.

  3. Mitchell PJ, Rabau MY, Haboubi NY. Indeterminate colitis. Tech Coloproctol 2007; 11: 91-6.

  4. Schultz MButt A. Is the north to south gradient in inflammatory bowel disease a global phenomenon? Expert Review of Gastroenterology & Hepatology 2012; 6(4): 445-7.

  5. Vind I, Riis L, Jess T, Knudsen E. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101(6): 1274-82.

  6. Yapp T, Stenson R, Thomas G. Crohn’s disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol 2000; 12(8): 907-11.

  7. Rubin G, Hungin A, Kelly P. Inflammatory bowel disease: epidemiology and management in an English general practice population. Alimentary Pharmacology and Therapeutics 2000; 14(12): 1553-9.

  8. Loftus C, Loftus E, Harmsen S. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflammatory Bowel Diseases 2007; 13(3): 254-61.

  9. Bernstein C, Wajda A, Svenson L. The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study. Am J Gastroenterol 2006; 101(7): 1559-68.

  10. Cosnes J, Gower-Rousseau C, Seksik P. Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology 2011; 140(6): 1785-94.

  11. Hou J, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: A systematic review. Am J Gastroenterol 2009; 104(8): 2100-9.

  12. Yamamoto-Furusho J. Clinical Epidemiology of Ulcerative Colitis in Mexico. J Clin Gastroenterol 2009; 43(3): 221-4.

  13. Hou J, El-Serag H, Sellin J, Thirumurthi S. Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. Dig Dis Sci 2011; 56(5): 1476-81.

  14. MacDonald T, Monteleone I, Fantini M. Regulation of Homeostasis and Inflammation in the Intestine. Gastroenterology 2011; 140(6): 1768-75.

  15. Loftus E, Schoenfeld P, Sandborn W. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Alimentary Pharmacology and Therapeutics 2002; 16(1): 51-60.

  16. Strober W, Asano N, Fuss I. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn’s disease. Immunol Rev 2014; 260(1): 249-60.

  17. Van der Heide F,Dijkstra A, Weersma RK. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15(8): 1199-207.

  18. Kaplan G, Jackson T, Sands B. The Risk of developing Crohn’s disease after an appendectomy: A meta-analysis. Am J Gastroenterol 2008; 103(11): 2925-31.

  19. Andersson R, Olaison G, Tysk C. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003; 124(1): 40-6.

  20. Ferrer I, Hinojosa del Val J. Definiciones, manifestaciones clínicas y diagnóstico de la enfermedad de Crohn. Medicine 2012; 11(5): 257-65.

  21. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn’s disease. Autoimmunity Reviews 2014; 467-71.

  22. Etzel J, Larson M, Anawalt B. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflammatory Bowel Diseases 2011; 17(10): 2122-9.

  23. Robinson RJ,?Iqbal SJ,?Al-Azzawi F,?et al. Sex hormone status and bone metabolism in men with Crohn’s disease. Aliment Pharmacol Ther?1998; 12(1): 21-5.

  24. Wilkins T, Jarvis K, Patel J.?Diagnosis and management of Crohn’s disease?American Family Physician 2011; 84(12): 1365-75.

  25. Strong S, Steele SR, Boutrous M. Clinical Practice Guideline for the Surgical Management of Crohn’s Disease. Dis Colon Rectum 2015; 58(11): 1021-36.

  26. Ailsa L. Hart, Siew C. Crohn’s disease. Inflammatory Bowel Disease; 43(5): 282-90.

  27. Murawska N, Fabisiak A, Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases. Inflammatory Bowel Diseases 2016; 22(5): 1198-208.

  28. Brakenhoff L, Heijde D, Hommes D. IBD and arthropathies: a practical approach to its diagnosis and management. Gut; 60(10): 1426-35.

  29. Uko V, Thangada S, Radhakrishnan K. Liver Disorders in Inflammatory Bowel Disease. Gastroenterology Research and Practice 2012; 2012.

  30. Battat R, Kopylov U, Szilagyi A. Vitamin B12 deficiency in inflam- matory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis 2014; 20(6): 1120-8.

  31. Kazmierczak IK, Wysocka E, Szymczak A. Osteoprotegerin, s- RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn’s disease. Prz Gastroenterol 2016; 11(1): 30-4.

  32. Fraser C, Satish K, Simon P. Medical management of Crohn’s disease. BMJ 2008; 336.

  33. Thad W, Athryn J, Jigneshkumar P. Diagnosis and management of Crohn’s disease. Am Fam Physician?2011; 84(12): 1365-75.

  34. Quinton J, Sendid B, Reumaux D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42(6): 788-91.

  35. Yazici D, Aydin S, Yavuz D. Anti-Saccaromyces cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid diseae. Endocrine 2010; 38(2): 194-8.

  36. Satsangi J, Silverberg MS, Vermeire S. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.

  37. Sandborn W, Feagan B, Hanauer S. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122(2): 512-30.

  38. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease Activity. Lancet 1980; 1: 514.

  39. Best W, Becktel J, Singleton J. Development of a Crohn’s disease activity index?Gastroenterology 1976; 70(3): 439-44.

  40. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2013; (4): CD000545.

  41. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.

  42. Seow CH, Benchimol EI, Griffiths AM. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008:CD000296.

  43. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.

  44. Arora S, Katkov W, Cooley J. Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-9.

  45. Feagan BG, Fedorak RN, Irvine EJ, Wild G. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 1627-32.

  46. Fraser AG. Methotrexate: first-line or second line immunomodulator? Eur J Gastroenterol Hepatol 2003; 15: 225-31.

  47. Narula N, Kainz S, Petritsch W. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti- TNF-α naïve Crohn’s disease. Aliment Pharmacol Ther 2016; 44(2): 170-80.

  48. Takeshima F, Yoshikawa D, Higashi S. Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan. BMC Gastroenterology 2016; 16: 82.

  49. Loftus EV Jr., Colombel JF, Schreiber S. Safety of long-term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical t r i a l s . Clin Gastroenterol Hepatol 2016. pii: S1542- 3565(16)30440-2.

  50. Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol 2016; 29: 243-8.

  51. Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther 2016: 1-14.

  52. Khanna R, Mosli MH, Feagan BG. Anti-Integrins in Ulcerative Colitis and Crohn’s Disease: What is their place? Dig Dis 2016; 34(1-2): 153-9.

  53. Lichtenstein L, Avni-Biron I, Ben-Bassat O. Probiotics and prebiotics in Crohn’s disease therapies. Best Pract Res Clin Gastroenterol 2016; 30(1): 81-8.

  54. Mowat C, Cole A, Windsor A, Ahmad T. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571-607.

  55. Louis E, Collard A, Oger AF. Behavior of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-82.




2020     |     www.medigraphic.com